DE69511279T2 - Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen - Google Patents

Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen

Info

Publication number
DE69511279T2
DE69511279T2 DE69511279T DE69511279T DE69511279T2 DE 69511279 T2 DE69511279 T2 DE 69511279T2 DE 69511279 T DE69511279 T DE 69511279T DE 69511279 T DE69511279 T DE 69511279T DE 69511279 T2 DE69511279 T2 DE 69511279T2
Authority
DE
Germany
Prior art keywords
carbones
lung
drug delivery
increase drug
liquid fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69511279T
Other languages
English (en)
Other versions
DE69511279D1 (de
Inventor
Gwen Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Publication of DE69511279D1 publication Critical patent/DE69511279D1/de
Application granted granted Critical
Publication of DE69511279T2 publication Critical patent/DE69511279T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0476—Oxygenated solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/913—Breathable liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69511279T 1994-11-04 1995-11-02 Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen Expired - Fee Related DE69511279T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/334,688 US5531219A (en) 1994-11-04 1994-11-04 Use of liquid fluorocarbons to facilitate pulmonary drug delivery
PCT/US1995/014280 WO1996014056A1 (en) 1994-11-04 1995-11-02 Use of liquid fluorocarbons to facilitate pulmonary drug delivery

Publications (2)

Publication Number Publication Date
DE69511279D1 DE69511279D1 (de) 1999-09-09
DE69511279T2 true DE69511279T2 (de) 2000-01-05

Family

ID=23308353

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69511279T Expired - Fee Related DE69511279T2 (de) 1994-11-04 1995-11-02 Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen

Country Status (10)

Country Link
US (1) US5531219A (de)
EP (1) EP0789558B1 (de)
JP (1) JPH10508602A (de)
AT (1) ATE182785T1 (de)
AU (1) AU710381B2 (de)
DE (1) DE69511279T2 (de)
DK (1) DK0789558T3 (de)
ES (1) ES2136315T3 (de)
GR (1) GR3031504T3 (de)
WO (1) WO1996014056A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124260T3 (es) * 1991-05-03 1999-02-01 Alliance Pharma Respiracion liquida parcial de fluorocarbonos.
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5829428A (en) * 1996-05-29 1998-11-03 Alliance Pharmaceutical Corp. Methods and apparatus for reducing the loss of respiratory promoters
WO1998006426A1 (en) * 1996-08-14 1998-02-19 Gram Joergen Brodersen Use of a plasminogen activator for the treatment of pulmonary disorders
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
CN1123345C (zh) * 1997-02-17 2003-10-08 奥坦纳医药公司 治疗ards或irds的组合物
US20040219149A1 (en) * 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
EP1379306A1 (de) * 2001-04-11 2004-01-14 Michael Kandler Vorrichtung zur künstlichen beatmung
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CA2413041A1 (fr) * 2002-11-29 2004-05-29 Jean-Paul Praud Un appareil permettant d'effectuer des ventilations liquides totales
GB2422310B (en) * 2004-12-02 2006-12-27 Kaizen Matsumoto Carcinogen solvents in reducing the carcinogen concentration of cells
US7909031B2 (en) * 2005-06-09 2011-03-22 Temple Univesity - Of The Commonwealth System of Higher Education Process for transient and steady state delivery of biological agents to the lung via breathable liquids
WO2007071052A1 (en) * 2005-12-21 2007-06-28 Uti Limited Partnership Treatment of respiratory diseases
US9351943B2 (en) * 2010-07-01 2016-05-31 Matthew T. McLeay Anti-fibroblastic fluorochemical emulsion therapies
EP3065705A4 (de) * 2013-11-04 2017-10-18 Board of Regents, The University of Texas System Zusammensetzungen und verfahren zur verabreichung eines enzyms an den atemweg einer person
US9028401B1 (en) 2013-11-11 2015-05-12 Cross Bay Medical, Inc. Apparatus and methods for accessing and sealing bodily vessels and cavities
US10034986B2 (en) 2013-11-11 2018-07-31 Crossbay Medical, Inc. Method and apparatus of tubal patency catheter and delivery systems
US10245074B2 (en) 2013-11-11 2019-04-02 Crossbay Medical, Inc. Apparatus and methods for accessing and sealing bodily vessels and cavities
WO2016179447A1 (en) * 2015-05-06 2016-11-10 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
US11318041B2 (en) 2019-10-09 2022-05-03 Crossbay Medical, Inc. Apparatus and method for everting catheter for IUD delivery and placement in the uterine cavity
WO2022081556A1 (en) * 2020-10-12 2022-04-21 Boundless Science, Llc Systems, devices and methods for delivering aerosolized fluorocarbons

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
JP2935519B2 (ja) * 1989-08-28 1999-08-16 シーキンス，ケイ・マイケル 超音波および／またはペルフルオロカーボン液での対流を介する肺癌高熱治療
US5437272A (en) * 1991-05-01 1995-08-01 Alliance Pharmaceutical Corp. Perfluorocarbon associated gas exchange
ES2124260T3 (es) * 1991-05-03 1999-02-01 Alliance Pharma Respiracion liquida parcial de fluorocarbonos.
US5209785A (en) * 1991-10-30 1993-05-11 United Technologies Corporation Non-chlorinated solvent dewax process

Also Published As

Publication number Publication date
DK0789558T3 (da) 2000-03-06
WO1996014056A1 (en) 1996-05-17
GR3031504T3 (en) 2000-01-31
DE69511279D1 (de) 1999-09-09
US5531219A (en) 1996-07-02
EP0789558A1 (de) 1997-08-20
ATE182785T1 (de) 1999-08-15
EP0789558B1 (de) 1999-08-04
AU4101796A (en) 1996-05-31
ES2136315T3 (es) 1999-11-16
AU710381B2 (en) 1999-09-16
JPH10508602A (ja) 1998-08-25

Similar Documents

Publication Publication Date Title
DE69511279D1 (de) Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen
Berg et al. Precountershock cardiopulmonary resuscitation improves ventricular fibrillation median frequency and myocardial readiness for successful defibrillation from prolonged ventricular fibrillation: a randomized, controlled swine study
EE200000194A (et) Perforeeritud mikropartiklid ja nende kasutamise meetodid
Taylor et al. Requirements for target‐controlled infusion of propofol to insert the laryngeal mask airway
Garner et al. Airway pressure release ventilation (APRV): a human trial
DE69725379D1 (de) Dosiervorrichtung zur Zuführung von zusätzlichem Gas oder Flüssigkeit im Atemgas eines Anästhesie- oder Beatmungsgerätes
WO2006016953A3 (en) Bis closed loop anesthetic delivery
PT813424E (pt) Formas de dosagem farmaceutica oral que contem um inibidor da bomba de protoes e um agente antacido ou alginato
ATE219678T1 (de) Wirkstoff zur stimulation von hartem gewebe
DE69738000D1 (de) Neue Arzneiformulierung enthaltend Budesonide
ATE531364T1 (de) Verwendung von mometason-furoat in einer adjuvans-therapie
ATE281828T1 (de) Nikotininhalator
ATE88878T1 (de) Kuenstliche druese zur implantation in den menschlichen koerper.
HUP9904075A2 (hu) Loratidint és egy decongestanst tartalmazó készítmény asztma kezelésére
DE69705319D1 (de) Vorrichtung mit mehreren strömungspfaden zur oralen verabreichung von boluseinheiten
DK0799035T3 (da) Emulsion egnet til indgivelse af et sphingolipid og anvendelse deraf
BR9713514A (pt) Novo uso de creatina
DE59712344D1 (de) Verwendung von peptidischen Bradykinin-Antagonisten zur Herstellung von Arzneimitteln
ATE145827T1 (de) Verfahren zur hemmung der sauerstofftoxizität in den lungen
Fujii et al. Midazolam versus propofol for reducing contractility of fatigued canine diaphragm
Campion et al. Re: End-tidal carbon dioxide underestimates plasma carbon dioxide during emergent trauma laparotomy leading to hypoventilation and misguided resuscitation: A Western Trauma Association Multicenter study
Chetty et al. Chronic respiratory failure due to bilateral vocal cord paralysis managed with nocturnal nasal positive pressure ventilation
HRP20080389A2 (en) THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
Mohnke et al. Ultra-low tidal volume ventilation during cardiopulmonary resuscitation shows no mitigating effect on pulmonary end-organ damage compared to standard ventilation: insights from a porcine model
DE69530600D1 (de) Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee